<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114426">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02057367</url>
  </required_header>
  <id_info>
    <org_study_id>ANE2556-01510</org_study_id>
    <nct_id>NCT02057367</nct_id>
  </id_info>
  <brief_title>Scalp Nerve Block and Opioid Consumption in Brain Surgery</brief_title>
  <official_title>The Effect of Pre-incisional Anterior Scalp Block on Intraoperative Opioid Consumption in Adult Patients Undergoing Elective Craniotomy to Remove Tumor: A Prospective Randomized Controlled</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiang Mai University</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anterior scalp block with 0.5% plain Marcaine 20 ml. may reduce the intraoperative opioid
      consumption in neurosurgical patients who undergoing the supratentorial craniotomy compared
      to those who receive 0.9% normal saline solution (placebo).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anterior scalp block with 0.5% plain Marcaine 20 ml. may reduce the intraoperative opioid
      consumption in neurosurgical patients who undergoing the supratentorial craniotomy compared
      to those who receive 0.9% normal saline solution (placebo).

      A Prospective Randomized Double Blind Control
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Intraoperative opioid consumption</measure>
    <time_frame>During the supratentorial craniotomy surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>The overall intravenous fentanyl consumption (microgram/ kilogram) during the surgery. The decision to administer fentanyl is guided by the changes of blood pressure and/ or heart rate greater than 20% from baseline level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>systolic blood pressure change</measure>
    <time_frame>within 5 minutes after skull pin insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>The maximal systolic blood pressure within the first 5 minutes after skull pin insertion will be recorded.
The systolic blood pressure change from baseline will be calculated. The unit is mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate change</measure>
    <time_frame>within 5 minutes after skull pin insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>The maximal heart rate within the first 5 minutes after skull pin insertion will be recorded.
The heart rate change from baseline level will be calculated. The unit is beats per minute.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>extubation</measure>
    <time_frame>end of surgery, before transferring to the intensive care unit</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rate of immediate extubation before transferring to the intensive care unit (ICU) compared between patients who received 0.5% plain Marcaine and 0.9% normal saline solution.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Brain Tumour</condition>
  <arm_group>
    <arm_group_label>Scalp block with 0.5% plain marcaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anterior scalp block with 0.5% plain Marcaine 20 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Scalp block with 0.9% normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Anterior scalp block with 0.9% normal saline 20 ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scalp block with 0.5% plain Marcaine</intervention_name>
    <description>Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.</description>
    <arm_group_label>Scalp block with 0.5% plain marcaine</arm_group_label>
    <other_name>Code 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scalp block with 0.9% normal saline</intervention_name>
    <description>Anterior scalp block will be done by using 0.9% normal saline 20 ml.</description>
    <arm_group_label>Scalp block with 0.9% normal saline</arm_group_label>
    <other_name>Code 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who have supratentorial brain tumor

          2. Patients have been scheduled to undergo an elective craniotomy to remove tumor in any
             surgical position

          3. Patients have been general anesthetized with endotracheal intubation and control
             ventilation

          4. Patients who have provided consent for the participation in the research and for the
             use of their medical record in research

        Exclusion Criteria:

          1. Pregnant patients

          2. Patients who have a history of local anesthetic allergy and/ or anaphylaxis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pathomporn Pin-on, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chiang Mai University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiang Mai University</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiang Mai University</investigator_affiliation>
    <investigator_full_name>Pathomporn Pin on, M.D.</investigator_full_name>
    <investigator_title>Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>supratentorial brain tumour</keyword>
  <keyword>craniotomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
